Role of norepinephrine in the pathophysiology and treatment of mood disorders

Biological Psychiatry

Volumn 46, Issue 9, 1999, Pages 1219-1233

  Ressler, Kerry J ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Mood disorder; Noradrenaline; Norepinephrine; Pathophysiology

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ALPHA ADRENERGIC RECEPTOR; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BETA ADRENERGIC RECEPTOR; CARRIER PROTEIN; CATECHOLAMINE; CLONIDINE; DOPAMINE; GROWTH HORMONE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; REBOXETINE; RESERPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TYROSINE 3 MONOOXYGENASE; VENLAFAXINE;

ADAPTATION; AFFECTIVE NEUROSIS; AROUSAL; ATTENTION; BRAIN STEM; CATECHOLAMINE METABOLISM; CATECHOLAMINE SYNTHESIS; CELL TRANSPORT; DEPRESSION; DOPAMINE RELEASE; ENZYME ACTIVITY; HEREDITY; HUMAN; LOCUS CERULEUS; MANIC DEPRESSIVE PSYCHOSIS; MEMORY; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEROTONIN RELEASE; SLEEP; STRESS;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; LOCUS COERULEUS; MOOD DISORDERS; NOREPINEPHRINE;

EID: 0033232510     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00127-4     Document Type: Review

References (113)

1. Amara S., Kuhar M. Neurotransmitter transporters Recent Progress . Ann Rev Neurosci. 16:1993;73-93.
2. Andrade R., Aghajanian G.K. Opiate and a2-adrenoceptor induced hyperpolarization of locus coeruleus neurons in brain slices Reversal by cyclic adenosine 3′:5′ monophosphate analogues . J Neurosci. 5:1985;2359-2364.
3. Andrews J., Ninan P.T., Nemeroff C.B. Venlafaxine A novel antidepressant that has a dual mechanism of action . Depression. 4:1996;48-56.
4. Arango V., Underwood M.D., Mann J.J. Fewer pigmented locus coeruleus neurons in suicide victims Preliminary results . Biol Psychiatry. 39:1996;112-120.
5. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor (CRF) in depression and anxiety disorders. J Endocrinol. 160:1999;1-12.
6. Ascher J.A., Cole J.A., Colin S.N., et al. Bupropion A review of its mechanism of antidepressant activity . J Clin Psych. 56:1995;395-401.
7. Aston-Jones G., Chiang C., Alexinsky T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res. 88:1991;501-520.
8. Aston-Jones G., Shipley M., Chouvet G., et al. Afferent regulation of locus coeruleus neurons Anatomy, physiology and pharmacology . Prog Brain Res. 85:1991;47-75.
9. 3H-Norepinephrine by tissues. Science. 133:1961;383-384.
10. Baron B., Ogden A., Siegel B. Rapid down-regulation of B-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol. 154:1988;125-134.
11. Bellivier F., Leboyer M., Courtet P., et al. Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry. 55:1998;33-37.
12. Berman R., Krystal J., Charney D. Mechanism of action of antidepressants Monoamine hypotheses and beyond . Watson S. Biology of Schizophrenia and Affective Disease. 1996;295-368 American Psychiatric Press Inc, Washington, DC.
13. Biegon A., Fieldust S. Reduced tyrosine hydroxylase immunoreactivity in locus coeruleus of suicide victims. Synapse. 10:1992;79-82.
14. Blomberg P., Kopin I., Gordon E., Markey S., Ebert M. Conversion of MHPG to vanillylmandelic acid. Arch Gen Psychiatry. 37:1980;1095-1098.
15. Bunney W.E., Davis J.M. Norepinephrine in depressive reactions A review . Arch Gen Psychiatry. 13:1965;483-494.
16. Chan-Palay V., Asan E. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression. J Comp Neurol. 287:1989;357-372.
17. Charney D. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 59:(suppl 14):1998;11-14.
18. Charney D., Heninger G., Sternberg D., et al. Presynaptic adrenergic receptor sensitivity in depression The effect of long-term desipramine treatment . Arch Gen Psychiatry. 38:1981;1334-1340.
19. Cleare A., Murray R., O'Keane V. Do noradrenergic reuptake inhibitors affect serotonergic function in depression? Psychopharmacology. 134:1997;406-410.
20. Cole B., Robbins T. Forebrain norepinephrine Role in controlled information processing in the rat . Neuropsychopharmacology. 7:1992;129-141.
21. Costa E., Sandler M. Monoamine Oxidase New Vistas . 1972;Raven Press, New York.
22. DeBellis M., Geracioti T., Altemus M., et al. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biol Psychiatry. 33:1993;636-641.
23. deBoer T. The pharmacologic profile of mirtazepine. J Clin Psychiatry. 57:(suppl 4):1996;19-25.
24. Delgado P., Charney D., Price L., et al. Serotonin function and the mechanism of antidepressant action Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan . Arch Gen Psychiatry. 47:1990;411-418.
25. Delgado P., Miller H., Salomon R., et al. Monoamines and the mechanism of antidepressant action Effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull. 29:1993;389-396.
26. DeParmentier F., Cheetham S., Crompton M., Katona C., Horton R. Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res. 525:1990;71-77.
27. Drevets W. Functional neuroimaging studies of depression The anatomy of melancholia . Ann Rev Med. 49:1998;341-361.
28. Duman R., Heninger G., Nestler E. A molecular and cellular theory of depression. Arch Gen Psychiatry. 54:1997;597-606.
29. Epstein C., Figiel G., McDonald W., Amazon-Leece J., Figiel L. Rapid rate transcranial magnetic stimulation in young and middle-aged refractory depressed patients. Psych Annals. 28:(1):1998;36-39.
30. Foote S., Aston-Jones G. Pharmacology and physiology of central noradrenergic systems. Bloom F., Kupfer D. Psychopharmacology The Fourth Generation of Progress . 1995;335-345 Raven Press Ltd, New York.
31. Freis E. Mental depression in hypertensives treated for long periods with large doses of reserpine. N Engl J Med. 251:(Dec 16):1954;1006-1008.
32. Garcia-Sevilla J., Zis A., Hollingsworth P., Greden J., Smith C. Platelet alpha2-adrenergic receptors in major depressive disorders Binding of tritiated clonidine before and after tricyclic antidepressant drug treatment . Arch Gen Psychiatry. 38:1981;1327-1333.
33. Geracioti T., Loosen P., Ekhator N., et al. Uncoupling of serotonergic and noradrenergic systems in depression Preliminary evidence from continuous cerebrospinal fluid sampling . Depress Anxiety. 6:(3):1997;89-94.
34. Ghosh A., Carnahan J., Greenberg M. Requirement for BDNF in activity-dependent survival of cortical neurons. Science. 263:1994;1618-1623.
35. Glowinski J., Axelrod J. Inhibition of uptake of tritiated-noradrenaline in the intact rat brain by imipramine and structurally related compounds. Nature. 204:1964;1318-1319.
36. Goodman C.S., Shatz C.J. Developmental mechanisms that generate precise patterns of neuronal connectivity. Cell. 10:(suppl):1993;77-98.
37. Goodwin F.K., Bunney W.E. Depressions following reserpine A re-evaluation . Semin Psychiatry. 3:1971;435-448.
38. Greenhoff J., Nisell M., Ferre S., Aston-Jones G., Svensson T. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm. 93:1993;11-25.
39. Heninger G., Delgado P., Charney D. The revised monoamine theory of depression A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans . Pharmacopsychiatry. 29:1996;2-11.
40. Hosada K., Duman R. Regulation of beta-1-adrenergic receptor mRNA and ligand binding by antidepressant treatment and norepinephrine depletion in rat frontal cortex. J Neurochem. 60:1993;1335-1343.
41. Javaid J., Rubinstein J., Davis J. Effects of pharmacological agents on MHPG. Maas J. MHPG Basic Mechanisms and Psychopathology . 1983;45-67 Academic Press, New York.
42. Karege F., Bovier P., Gaillard J., Tissot R. Plasma MHPG and AMDP depression relations, evolution and drug effect in a follow up study of depressed patients. Hum Psychopharmacol. 6:1991;11-17.
43. Karege F., Bovier P., Widmer J., Gaillard J., Tissot R. Platelet membrane alpha-2-adrenergic receptors in depression. Psychiatry Res. 43:1992;243-252.
44. Kasamatsu T., Itakura T., Johnson G., et al. Neuronal plasticity in cat visual cortex A proposed role for the central noradrenaline system . Descarries L., Reader T., Jasper H. Monoamine Innervation of Cerebral Cortex. 1984;301-320 Alan R Liss Inc, New York.
45. Kelly C., Cooper S. Differences and variability in plasma noradrenaline between depressive and anxiety disorders. J Psychopharmacol. 12:1998;161-167.
46. Kitayama I., Nakamura S., Yaga T., et al. Degeneration of locus coeruleus axons in stress-induced depression model. Brain Res Bull. 35:1994;573-580.
47. Kitayama I., Yaga T., Kayahara T., et al. Long-term stress degenerates, but imipramine regenerates, noradrenergic axons in the rat cerebral cortex. Biol Psychiatry. 42:1997;687-696.
48. Klimek V., Stockmeier C., Overholser J., Meltzer H.Y., Kalka S., Dilley G., Ordway G. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 17:(21):1997;8451-8458.
49. Kuhn R. The treatment of depressive states with G22355 (Imipramine Hydrochloride). Am J Psychiatry. 115:1958;459-464.
50. Kunugi H., Vallada H., Hoda F., et al. No evidence for an association of affective disorders with high- or low-activity allele of catechol-o-methyltransferase gene. Biol Psychiatry. 42:(4):1997;282-285.
51. Leonard B. The role of noradrenaline in depression A review . J Psychopharmacol. 11:(suppl 4):1997;S39-S47.
52. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 274:1996;1527-1531.
53. Levitt P., Rakic P., Goldman-Rakic P. Comparative assessment of monoamine afferents in mammalian cerebral cortex. Descarries L., Reader T., Jasper H. Monoamine Innervation of Cerebral Cortex. 1984;41-60 Alan R Liss Inc, New York.
54. Lindvall O., Bjorklund A. General organization of cortical monoamine systems. Descarries L., Reader T., Jasper H. Monoamine Innervation of Cerebral Cortex. 1984;9-40 Alan R Liss Inc, New York.
55. Lingjaerde O. Tetrabenazine (Nitroman) in the treatment of psychoses. Acta Psychiatr Scand. 39:(suppl 170):1963;1-109.
56. Loomer J., Sunders J., Kline N. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiat Res Rep Am. 8:1957;129-141.
57. Maas J., Fawcett J., Dekirmenjian H. Catecholamine metabolism, depressive illness and drug response. Arch Gen Psychiatry. 26:1972;252-262.
58. Mann J., Underwood M., Arango V. Postmortem studies of suicide victims. Watson S. Biology of Schizophrenia and Affective Disease. 1996;197-222 American Psychiatric Press Inc, Washington, DC.
59. Matussek N., Ackenheil M., Hippius H., et al. Effects of clonidine on growth hormone release in psychiatric patients and controls. Psychiatry Res. 2:1980;25-36.
60. McGuffin P., Katz R. The genetics of depression and manic depressive disorder. Br J Psychiatry. 155:1989;294-304.
61. Meana J., Barturen F., Garcia-Sevilla J. a2-adrenoceptors in the brains of suicide victims Increased receptor density associated with major depression . Biol Psychiatry. 31:1992;471-490.
62. Melia K.R., Nestler E.J., Duman R.S. Chronic imipramine treatment normalizes levels of tyrosine hydroxylase in the locus coeruleus of chronically stressed rats. Psychopharmacol. 108:1992;23-26.
63. Moldin S., Reich T., Rice J. Current perspectives on the genetics of unipolar depression. Behav Genet. 21:(3):1991;211-242.
64. Mongeau R., Blier P., de Montigny C. The serotonergic and noradrenergic systems of the hippocampus Their interactions and the effects of antidepressant treatments . Brain Res Brain Res Rev. 23:1997;145-195.
65. Montgomery S. Reboxetine Additional benefits to the depressed patient . J Psychopharmacol. 11:(suppl 4):1997;S9-S15.
66. Muller J., Pryer W., Gibbons J., Orgain E. Depression and anxiety occurring during Rauwolfia therapy. JAMA. 159:1955;836-839.
67. Muscettola G., Potter W., Pickar D., et al. Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders A replication and new findings . Arch Gen Psychiatry. 41:1984;337-342.
68. Muth E., Haskins J., Moyer J., et al. Antidepressant biochemical profile of the novel bicyclic compound WY-45,030, an ethyl-cyclohexanol derivative. Biochem Pharmacol. 35:1986;4493-4497.
69. Nathan K., Musselman D., Schatzberg A., Nemeroff C. Biology of mood disorders. Schatzberg A., Nemeroff C. Textbook of Psychopharmacology. 1995;439-477 American Psychiatric Press Inc, Washington, DC.
70. Nestler E., McMahon A., Sabban E., Tallman J., Duman R. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci U S A. 87:1990;7522-7526.
71. Nibuya M., Morinobu S., Duman R. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 15:1995;7539-7547.
72. Nibuya M., Nestler E., Duman R. Chronic antidepressant administration increases the expression of cAMP response element-binding protein (CREB) in rat hippocampus. J Neurosci. 16:1996;2365-2372.
73. Ohara K., Nagai M., Suzuki Y., Ohara K. Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport. 9:1998;1305-1308.
74. Ordway G.A., Smith K.S., Haycock J.W. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J Neurochem. 62:1994;680-685.
75. Ordway G.A., Widowson P.S., Smith K.S., Halaris A.E. Agonist binding to α2 adrenoceptors is elevated in the locus coeruleus from victims of suicide. J Neurochem. 63:1994;617-624.
76. Owens M.J. Molecular and cellular mechanisms of antidepressant drugs. Depress Anxiety. 4:1997;153-159.
77. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressant and their metabolites. J Pharmacol Exp Ther. 283:1997;1305-1322.
78. Owens M.J., Ieni J.R., Knight D.L., Winders K., Nemeroff C.B. The serotonergic antidepressant nefazodone inhibits the serotonin transporter In vivo and ex vivo studies . Life Sci. 57:1995;373-380.
79. Papadopoulos G., Parnavelas J., Buijs R. Monoaminergic fibers form conventional synapses in the cerebral cortex. Neurosci Lett. 76:1990;275-279.
80. Papolos D., Veit S., Faedda G., Saito T., Lachman H. Ultra-ultra rapid cycling bipolar disorder is associated with the low activity catecholamine-O-methyltransferase allele. Mol Psychiatry. 3:1998;346-349.
81. 1-imidazoline receptors in mood disorders. Ann N Y Acad Sci. 763:1995;510-519.
82. Piletz J., Schubert D., Halaris A. Evaluation of studies in platelet alpha2-adrenoceptors in depressive illness. Life Sci. 39:1986;1589-1616.
83. Pitts W., Fann W., Halaris A., et al. Bupropion in depression A tri-center placebo controlled study . J Clin Psychiatry. 44:1983;95-100.
84. Plaznik A., Danysz W., Kostowski W., Bidzinski A., Hauptmann M. Interaction between noradrenergic and serotonergic brain systems as evidenced by microinjections of adrenergic agonists and antagonists into the median raphe nucleus. Pharmacol Biochem Behav. 19:1983;7-32.
85. Plotsky P., Owens M., Nemeroff C. Psychoneuroendocrinology of depression. Psychoneuroendocrinology. 21:1998;293-307.
86. Potter W., Grossman G., Rudorfer M. Noradrenergic function in depressive disorders. Mann J., Kupfer D. Biology of Depressive Disorders, Part A A Systems Perspective . 1993;1-27 Plenum Press, New York.
87. Potter W, Muscettola G, Goodwin F (1983): Sources of variance in clinical studies in MHPG. In Maas J (editor). MHPG: Basic Mechanisms and Psychopathology. New York: Academic Press, pp 145-165.
88. Potter W., Scheinin M., Golden R., et al. Selective antidepressant and cerebrospinal fluid Lack of specificity on noradrenaline and serotonin metabolism . Arch Gen Psychiatry. 42:1985;1171-1177.
89. Prange A. The pharmacology and biochemistry of depression. Dis Nerv Syst. 25:1964;217-221.
90. Robbins T., Everitt B. Central norepinephrine neurons and behavior. Bloom F., Kupfer D. Psychopharmacology The Fourth Generation of Progress . 1995;363-372 Raven Press Ltd, New York.
91. Roy A., Nielsen D., Rylander G., Sarchiapone M., Segal N. Genetics of suicide in depression. J Clin Psychiatry. 60:(suppl 2):1999;12-17.
92. Sackeim H., Prudic J., Devanand D., et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Eng J Med. 328:1993;839-846.
93. Schatzberg A. Noradrenergic vs. serotonergic antidepressants Predictors of treatment response . J Clin Psychiatry. 59:(Suppl 14):1998;15-18.
94. Schatzberg A., Samson J., Bloomingdale K., et al. Toward a biochemical classification of depressive disorders, X Urinary catecholamines, their metabolites, and D-type scores in subgroups of depressive disorders . Arch Gen Psychiatry. 46:1989;260-268.
95. Schatzberg A., Schildkraut J. Recent studies on norepinephrine systems in mood disorders. Bloom F., Kupfer D. Psychopharmacology The Fourth Generation of Progress . 1995;911-920 Raven Press Ltd, New York.
96. Schildkraut J. The catecholamine hypothesis of affective disorders A review of supporting evidence . Am J Psychiatry. 122:1965;509-522.
97. Schildkraut J., Orsulak P., Labrie R., et al. Toward a biochemical classification of depressive disorders. II. Application of multivariate discriminant function analysis to data on urinary catecholamines and metabolites. Arch Gen Psychiatry. 35:1978;1436-1439.
98. Schweizer E., Feighner J., Mandos L., et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry. 55:1994;104-108.
99. Serova L., Sabbau E.L., Zangea A., Overstreet D.H., Yadid G. Altered gene expression for catecholamine biosynthetic enzymes and stress response in a rat genetic model of depression. Brain Res Mol Brain Res. 63:(1):1998;133-138.
100. Serreti A., Maccaiardi F., Verga M., Cusin C., Pedrini S., Smeraldi E. Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. Am J Med Genetics. 81:(2):1998;127-130.
101. Shatz C.J. Impulse activity and the patterning of connections during CNS development. Neuron. 5:1990;745-756.
102. Siever L., Trestman R., Coccaro E. The growth hormone response to clonidine in acute and remitted depressed male patients. Neuropsychopharmacology. 6:1992;165-177.
103. Spector S., Sjoerdsma A., Udenfriend S. Blockade of endogenous norepinephrine synthesis by a-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J Pharmacol Exp Ther. 147:1965;86-95.
104. Spyraki C., Fibiger H. Functional evidence for subsensitivity of noradrenergic alpha2receptors after chronic desipramine treatment. Life Sci. 27:1980;186-1867.
105. Sulser F., Bickel M., Brodie B. The action of desmethylimipramine in counteracting sedation and cholinergic effects of reserpine-like drugs. J Pharmacol Exp Ther. 144:1964;321-330.
106. Valentino R., Aston-Jones G. Physiological and anatomical determinants of locus coeruleus discharge. Bloom F., Kupfer D. Psychopharmacology The Fourth Generation of Progress . 1995;373-385 Raven Press Ltd, New York.
107. Valentino R., Foote S., Page M. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann N Y Acad Sci. 697:1993;171-187.
108. Vetulani J., Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generation system in limbic forebrain. Nature. 257:1975;495-496.
109. Wang P., Kitayama I., Nomura J. Tyrosine hydroxylase gene expression in the locus coeruleus of depression-model rats and rats exposed to short-term and long-term forced walking stress. Life Sci. 62:(23):1998;2083-2092.
110. Waterhouse B., Sessler F., Cheng H., Woodward D., Azizi A., Moises H. New evidence for a gating action of norepinephrine in central neuronal circuits of mammalian brain. Brain Res Bull. 21:1988;425-432.
111. Weiner N., Molinoff P. Catecholamines. Siegel G., Agranoff B., Albers R., Molinoff P. Basic Neurochemistry Molecular, Cellular, and Medical Aspects . 5th edition. 1994;261-281 Raven Press Ltd, New York.
112. Weiss J., Demetrikopoulos M., West C., Bonsall R. Hypothesis linking the noradrenergic and dopaminergic systems in depression. Depression. 3:1996;225-245.
113. Wheatley D., van Moffaert M., Timmerman L., Kremer C., Group M.-F.S. Mirtazapine Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder . J Clin Psychiatry. 59:(6):1998;306-312.